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Abstract
Introduction: HIV-associated cryptococcal, TB and pneumococcal meningitis are the leading causes of adult meningitis in sub-
Saharan Africa (SSA). We performed a systematic review and meta-analysis with the primary aim of estimating mortality from
major causes of adult meningitis in routine care settings, and to contrast this with outcomes from clinical trial settings.
Methods: We searched PubMed, EMBASE and the Cochrane Library for published clinical trials (defined as randomized-con-
trolled trials (RCTs) or investigator-managed prospective cohorts) and observational studies that evaluated outcomes of adult
meningitis in SSA from 1 January 1990 through 15 September 2019. We performed random effects modelling to estimate
pooled mortality, both in clinical trial and routine care settings. Outcomes were stratified as short-term (in-hospital or two
weeks), medium-term (up to 10 weeks) and long-term (up to six months).
Results and discussion: Seventy-nine studies met inclusion criteria. In routine care settings, pooled short-term mortality from
cryptococcal meningitis was 44% (95% confidence interval (95% CI):39% to 49%, 40 studies), which did not differ between
amphotericin (either alone or with fluconazole) and fluconazole-based induction regimens, and was twofold higher than pooled
mortality in clinical trials using amphotericin based treatment (21% (95% CI:17% to 25%), 17 studies). Pooled short-term mor-
tality of TB meningitis was 46% (95% CI: 33% to 59%, 11 studies, all routine care). For pneumococcal meningitis, pooled
short-term mortality was 54% in routine care settings (95% CI:44% to 64%, nine studies), with similar mortality reported in
two included randomized-controlled trials. Few studies evaluated long-term outcomes.
Conclusions: Mortality rates from HIV-associated meningitis in SSA are very high under routine care conditions. Better strate-
gies are needed to reduce mortality from HIV-associated meningitis in the region.
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1 | INTRODUCTION
Approximately 37 million people were living with HIV world-
wide in 2017, with over two-thirds in sub-Saharan Africa
(SSA) [1]. Although access to combined antiretroviral therapy
(ART) has improved, a large proportion of people living with
HIV (PLHIV) still present with advanced immune suppression
and are at high risk for HIV-related infections [2,3]. Central
nervous system (CNS) infections are a major cause of mortal-
ity in PLHIV in SSA, with cryptococcal, TB and pneumococcal
meningitis the most common microbiologically confirmed aeti-
ologies [4,5]. Cryptococcal meningitis alone results in approxi-
mately 15% of HIV-associated deaths worldwide, with almost
three-quarters of these in SSA [6].
Treatment for HIV-associated meningitis is challenging even
in well-resourced settings. Recommended cryptococcal
meningitis management involves initial “induction” therapy with
intravenous amphotericin (ideally for one week with flucytosine
[7], which remains unavailable throughout most of Africa [8]), an
effective but highly toxic drug [9], followed by consolidation and
maintenance therapy with fluconazole [10]. However, less
potent fluconazole monotherapy is often used in resource-
constrained settings due to low cost, ease of oral administration
and better drug toxicity profile. Additionally, cryptococcal
meningitis survival is associated with performance of therapeu-
tic lumbar punctures (LPs) to reduce intracranial pressure (ICP)
[11,12], intravenous fluid (IVF) hydration and electrolyte supple-
mentation and monitoring to prevent life-threatening ampho-
tericin-related toxicities [9,10,13], and appropriate follow-up
after hospital discharge to initiate antiretroviral therapy (ART)
around four to six weeks to reduce the risk of immune-reconsti-
tution inflammatory syndrome [14]. Significant barriers exist to
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optimal management in most SSA settings, such as lack of more
potent antifungal drugs, lack of manometers to measure ICP,
hospital understaffing, limited laboratory services and loss to
follow-up after hospital discharge. Similarly, effective manage-
ment of TB meningitis is complicated in resource-constrained
settings with challenges in management of common antituber-
culous drug toxicities, long duration of treatment (of a minimum
of six months), poor sensitivity of diagnostic studies and delays
for culture results, emergence of drug resistance and lack of
integration of TB and HIV services [15,16]. Survival from pneu-
mococcal meningitis can be negatively affected by delayed
healthcare access and lack of timely initiation of effective
antimicrobial therapy [17].
Several systematic reviews have evaluated outcomes of
HIV-associated meningitides in Africa, but each has important
limitations. A recent review of long-term outcomes from HIV-
associated cryptococcal meningitis included only a small sub-
set of studies with long-term outcomes data which may not
be generally representative [18]. In a previous systematic
review of TB meningitis in Africa, investigators did not differ-
entiate between short- and long-term outcomes and combined
outcomes from studies using heterogeneous case definitions
(e.g. microbiologically diagnosed TB or TB diagnosed clinically
using various criteria), limiting interpretation [19]. A prior
well-conducted systematic review of pneumococcal meningitis
in Africa focused on paediatric populations [20].
Given the large burden and mortality from HIV-associated
meningitis in SSA and limitations of prior studies, we per-
formed a systematic review and meta-analysis to evaluate
short- and long-term outcomes of common HIV-associated
meningitides (cryptococcal, TB and pneumococcal). We esti-
mated mortality in “routine care” studies (which we defined as
studies in which hospital care was provided primarily by the
local medical team, for example, retrospective cohort studies),
providing realistic global burden estimates important for
resource allocation and prevention efforts such as cryptococ-
cal antigen (CrAg) screening [21]. We compared outcomes
from routine care to “clinical trial” studies (which we defined
as randomized-controlled trials (RCTs) or prospective cohorts
with regular day-to-day management of patients involving
study investigators) to characterize the outcomes gap and
provide insights into potential reductions in mortality that
might be realized through improved management strategies.
2 | METHODS
2.1 | Types of outcomes measures
Our overall aim was to determine the mortality associated
with the most common HIV-associated meningitides in sub-
Saharan Africa, captured at time points reflecting acute- and
long-term outcomes. Our mortality endpoints were defined as:
(1) Short-term (death ≤2 weeks after hospitalization or enrol-
ment); (2) medium-term (death ≤10 weeks); and long-term
(≤6 months). Study deviations from these pre-defined time-
points were described in the analysis.
2.2 | Types of studies and participants
We included published RCTs and observational studies (cohort
studies, case-control studies, cross-sectional audits or
surveillance studies) of adults (≥18-years) treated for crypto-
coccal, TB and/or pneumococcal meningitis. Inclusion criteria
included: (1) Study from sub-Saharan Africa (or restricted to
patients from sub-Saharan Africa in multi-centre studies with
participants also enrolled from outside of the region [22]); (2)
≥15 participants treated for cryptococcal, TB or pneumococcal
meningitis; and 3) full period of observation after 1990 (to
reflect emergence of HIV in SSA and modern antimicrobial
therapy regimens). Exclusion criteria included: (1) Paediatric
study or with a majority of patients <18-years old without dis-
aggregated results provided in adults; (2) case report, case
series, or <15 participants with cryptococcal, TB or pneumo-
coccal meningitis; (3) antimicrobial treatment not available or
treatment with therapies either not used or contraindicated
(e.g. acetazolamide for cryptococcal meningitis) [22,23]; (4)
non-representative or biased sampling (e.g. significant RCT
recruitment delay causing immortal time bias [14,24]; (5) miss-
ing mortality data for >15% of participants or mortality out-
comes not provided; (6) diagnostic criteria not clearly defined;
(7) repeat data from another study; or 8) not a full article (e.g.
conference abstract).
For cryptococcal meningitis, we included studies of cases
confirmed by cerebrospinal fluid (CSF) testing (i.e. positive
India ink, culture or CrAg), excluding those with a significant
number (>10%) of patients diagnosed through peripheral
blood CrAg testing alone, as blood CrAg testing is unable to
definitively confirm central nervous system involvement. For
TB meningitis, we included studies of either microbiologically
confirmed cases or with diagnostic criteria that combined CSF
findings and other supportive evidence, for example, isolation
of Mycobacterium tuberculosis at another site or suggestive
imaging [25]. For pneumococcal meningitis, we included stud-
ies with mortality for microbiologically confirmed cases or,
when results were not disaggregated with other cases, if a
majority of cases (>50%) were microbiologically confirmed.
These definitions were used so that outcomes would reflect
mortality from the aetiologies of interest rather than other
potential causes.
2.3 | Search method and data collection
We searched for studies from 1 January 1990 through 30
April 2018 using PubMed, EMBASE, and the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL). The search was
updated through 31 December 2018 in PubMed and
EMBASE with a subsequent update through 15 September
2019 in PubMed. Our search strategy combined geographic
and cryptococcal, TB and pneumococcal meningitis search
terms (Figure 1 and Appendix S1). We excluded conference
abstracts and studies that were not peer-reviewed. No restric-
tions were placed on age or language. The search strategy
and protocol was developed by the authors before the search;
the study protocol was not published.
Articles obtained in database searches were aggregated
and de-duplicated in Covidence [26]. Two reviewers (MWT
and AMG) independently performed a primary title and
abstract search to identify potentially eligible studies. The
authors then reviewed full text articles to assess for inclu-
sion, with data from included studies abstracted using stan-
dardized data collection forms. Secondary review was
provided by DSL and NW. Discrepancies were decided
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through consensus or adjudication from JNJ if needed. We
contacted authors as needed for clarification. Reference lists
of included articles as well as relevant reviews were
searched to identify other potential studies. We generated a
flow diagram, following PRISMA recommendations, and sum-
mary tables of excluded full-text articles with rationale (in
Appendix S1), and reporting was conducted per PRISMA
recommendations [27].
2.4 | Data synthesis and analysis
Data were pooled using standard random effects meta-analy-
ses for proportions, with variance of proportions stabilized
using Freeman-Tukey double arcsine transformation before
pooling [28]. We estimated the pooled proportion of deaths
and 95% confidence interval for each pathogen (Cryptococcus,
TB and pneumococcus) by study type (clinical trial vs routine
care study) and by timepoint (short-term, medium-term and
long-term mortality). Patient outcomes data were combined
for multiple routine care studies from the same facility if the
studies included patients from non-overlapping periods.
Heterogeneity was assessed with I2 values, representing the
percentage of total variability due to between-study hetero-
geneity. Results were presented using forest plots, along with
summary tables of study and patient characteristics (included
in Appendix S1). Analyses were conducted in R Studio using
the metaprop command [29].
2.5 | Sub-group analyses
We performed additional analyses to stratify estimates by
clinically important confounders. For cryptococcal meningitis,
we stratified outcomes by induction therapy; amphotericin B
with and without flucytosine (for <2 or ≥2 weeks), fluconazole
with flucytosine, fluconazole or treatment not specified. Out-
comes from induction regimens with amphotericin B alone or
amphotericin B with fluconazole were combined, as no mortal-
ity difference has been documented between groups [30,31].
For TB meningitis, we stratified analyses by studies with
microbiological-confirmed cases and with a majority of cases
defined using combined microbiological and clinical criteria
without Mycobacterium tuberculosis confirmed from CSF cul-
ture, smear or PCR. For pneumococcal meningitis, we strati-
fied analyses by treatment regimen. We further stratified
outcomes by region (Southern, Eastern, Middle (Central) and
Western Africa) as defined by the United Nations geoscheme
[32], and studies conducted after 2000 or before 2000. We
initially planned additional stratified analyses by HIV preva-
lence (≥50% or <50%) within a population, but most studies
included a majority or only HIV-positive patients and we
#1
Search (Africa[MeSH] OR Africa*[tiab] OR sub-Saharan[tiab] OR Angola[tiab] OR Benin[tiab] 
OR Botswana[tiab] OR Burkina[tiab] OR Burundi[tiab] OR Cameroon[tiab] OR Cape 
Verde[tiab] OR Cabo Verde[tiab] OR Chad[tiab] OR Comoros[tiab] OR Congo[tiab] OR Cote 
d’Ivoire[tiab] OR Ivory Coast[tiab] OR Equatorial Guinea[tiab] OR Eritrea[tiab] OR 
Ethiopia[tiab] OR Gabon[tiab] OR Gambia[tiab] OR Ghana[tiab] OR Guinea[tiab] OR 
Bissau[tiab] OR Guinea-Bissau[tiab] OR Kenya[tiab] OR Lesotho[tiab] OR Madagascar[tiab] 
OR Malawi[tiab] OR Mali[tiab] OR Mauritania[tiab] OR Mauritius[tiab] OR Mozambique[tiab] 
OR Namibia[tiab] OR Niger[tiab] OR Rwanda[tiab] OR Sao Tome and Principe[tiab] OR 
Senegal[tiab] OR Seychelles[tiab] OR Sierra Leone[tiab] OR Somalia[tiab] OR Sudan[tiab] OR 
Swaziland[tiab] OR Tanzania[tiab] OR Togo[tiab] OR Tunisia[tiab] OR Uganda[tiab] OR 
Western Sahara[tiab] OR Zambia[tiab] OR Zimbabwe[tiab])
#2
Search (Meningitis, Cryptococcal[Mesh] OR cryptococcus neoformans[mh] OR cryptococcus 
gattii[mh] OR cryptococcal meningitis[tiab] OR cryptococcal meningitides[tiab] OR cerebral 
cryptococcosis[tiab] OR cerebral cryptococcoses[tiab] OR toruloma[tiab] OR cryptococcus 
neoformans[tiab] OR (cryptococcal[tiab] OR cyptococcosis[tiab] OR cryptococcoses[tiab] OR 
Cryptococcus[tiab]) AND (meningitis[tiab])))
#3
Search (Tuberculosis, Meningeal[MeSH] OR TBM[tiab] OR tubercul* meningitis[tiab] OR TB 
meningitis[tiab] OR tubercul* cerebrospinal fluid[tiab] OR tubercul* CSF[tiab] OR (TB[tiab] 
OR tubercul*[tiab] AND (meningitis[tiab])))
#4
Search (Meningitis, Pneumococcal[MeSH] OR pneumococcal meningitis[tiab] OR streptococcus 
pneumon* meningitis[tiab] OR streptococcus meningitis[tiab] OR bacterial meningitis[tiab] OR 
(pneumococc*[tiab] OR streptococc*[tiab] AND (meningitis[tiab])))
 (Searching #1 and #2, #1 and #3, #1 and #4 limit search 1 Jan 1990 through 15 Sept 2019)
Figure 1. PubMed search strategy.
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therefore did not perform sub-group analyses based on HIV
status.
2.6 | Dealing with missing data and assessing risk
of bias
We described missingness of data, including clinical character-
istics (e.g. HIV status) and mortality. We performed intention-
to-treat analysis when multiple groups were compared. Out-
comes were reported for patients with known outcomes at
each mortality timepoint. This was done so as not to systemat-
ically bias estimates toward higher survival as would have
done if those lost to follow-up were all assumed to have sur-
vived. If loss to follow-up exceeded 15%, we excluded the
study from the analysis at that timepoint due to the high like-
lihood that outcomes were not missing at random (i.e. those
who died were more likely to be lost to follow-up). Given the
heterogeneity of study types, we undertook a subjective
assessment of study quality based on previous guidance for
systematic reviews [33]. This incorporated quality of reporting
of important covariates, for example, timing of ART in ART-
na€ıve patients treated for cryptococcal meningitis. Random-
ized-controlled trials of HIV-associated cryptococcal meningitis
have previously been assessed for risk of bias using GRADE
criteria [30].
3 | RESULTS AND DISCUSSION
3.1 | Overall search findings
The initial database search yielded 3661 titles, with two addi-
tional articles found that met inclusion criteria. After removing
duplicates, 2593 titles and abstracts were reviewed, with 272
selected for full text review. Of these, 193 were excluded
(Figure 2 and Appendix S1). Seventy-nine studies were
included from the primary database search and additional ref-
erences.
3.2 | Cryptococcal meningitis outcomes from
treatment provided under “routine care” settings
Forty-one observational studies with 10,139 cases of crypto-
coccal meningitis were included, most in HIV-positive patients
treated at district or referral hospitals (Appendix S1). The
majority of studies were judged of low quality, with limited
description of clinical management (e.g. performance of thera-
peutic lumbar punctures, antifungal therapy dose/duration,
timing of ART following initiation of antifungal therapy in ART-
na€ıve patients). Seventeen were prospective cohorts and one
was a mixed prospective and retrospective cohort [34], which
we classified as routine care studies. Three of these prospec-
tive cohorts described more active involvement from a study
team [[35–37]], but at irregular intervals with day-to-day man-
agement under local conditions. In 10% (4/41) of included
studies, the period of observation began prior to 2000. Seven-
teen countries were represented, with greatest representation
from South Africa (14 studies) [34,37–49], Ethiopia (three
studies) [50–52] and Uganda (three studies) [53–55]; other
countries had two or fewer studies [11,35,36,56–74]. Ampho-
tericin B-based induction therapy (with or without fluconazole)
was the predominant induction regimen in 16 studies,
fluconazole in 13 studies, and a mix of treatments (45% flu-
conazole and 43% amphotericin B) in one study [44], with
antifungal regimens not specified in 11 studies. In 28 studies
with details on ART status, 26% (1792/6777) had a history of
current or previous ART use. Reasons for exclusion are
detailed in Appendix S1; these included non-representative
sampling [24,75–77], high loss to follow-up or duration of fol-
low-up not clear [62,78], antifungal treatment not available
[23,79,80] and use of treatment regimens not used or con-
traindicated in management [81–83].
Short-term mortality was reported in 40/41 included stud-
ies (35 in-hospital and five studies with two-week mortality
reported). Pooled short-term mortality was 44% (95% CI:
39% to 49%, 40 studies), with high between-study hetero-
geneity (I2 = 89%) (Figure 3). Mortality was lowest in South-
ern Africa (37% (95% CI: 31% to 43%), I2 = 86%, 16 studies)
and highest in Central Africa (55% (95% CI: 41% to 69%),
I2 = 75%, three studies) and West Africa (54% (95% CI: 40%
to 67%), I2 = 83%, eight studies) (Figure S1). Restricting to
studies with a full observation period after 2000, pooled mor-
tality was 44% (95% CI: 39% to 49%, I2 = 90%, 36 studies)
(similar in a post-hoc analysis restricted to studies with a full
period of observation after 2005, with a pooled mortality of
42% (95% CI: 36% to 47%, I2 = 89%, 29 studies)). For these
studies, short-term mortality was 41% (95% CI: 32% to 51%,
I2 = 91%, 15 studies) with exclusive or predominant ampho-
tericin B-based induction therapy (none using flucytosine),
41% (95% CI: 31% to 50%, I2 = 89%, 11 studies) with exclu-
sive or predominant fluconazole, and 50% (95% CI: 39% to
61%, I2 = 78%, nine studies) with treatment not specified.
One study was excluded in which the proportion of patients
receiving amphotericin B-based and fluconazole induction
therapy was almost equivalent [44].
Few studies reported medium- or long-term mortality. Med-
ium-term mortality (defined as death ≤10-weeks, except ≤3-
months in one study) was described in five studies with 422
patients in Southern Africa (two studies) or East Africa (three
studies), with a pooled mortality of 51% (95% CI: 43% to 60%,
I2 = 60%) (Figure S2). Long-term mortality was described in
three studies (at nine months in one and 12 months in two
[35,42,56]) with 294 patients in Southern Africa (two studies)
and East Africa (one study). Pooled mortality was 63% (95% CI:
46% to 78%, I2 = 79%) (Figure S3). Studies from Botswana
[56], with standard amphotericin B and fluconazole induction
therapy, and Malawi [35], with high-dose fluconazole (800 mg/
day) induction therapy, reported one-year mortality of 65%
(142/219) and 77% (43/56) respectively among those not lost
to follow-up. The third study, a prospective cohort from South
Africa, reported a nine-month mortality of 37% (7/19) [42]. Few
participants in this study had baseline altered mental status
(11% (2/19) noted to have confusion), an established predictor
of mortality [84], and investigators may have recruited less seri-
ously ill patients. Regions in SSA with the highest acute mortal-
ity (Central and Western Africa) did not report long-term
mortality data.
3.3 | Cryptococcal meningitis outcomes for
treatment provided under clinical trial settings
We included 18 studies from clinical trials (randomized trials
or investigator-managed cohorts that compared ≥1 treatment
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regimen for cryptococcal meningitis) with a total of 2048
cases, almost all HIV positive. These included 10 RCTs and
eight prospective cohorts, most at referral centres and all con-
ducted after 2000 (Appendix S1). The quality was judged to
be good for most studies (details on therapeutic lumbar punc-
ture details in 12/18, timing of ART initiation in 17/18 and
description of antifungal regimen in all studies), and most
RCTs had been previously evaluated using GRADE criteria
[30]. Nine countries were represented (including several mul-
ti-country RCTs); greatest representation was from South
Africa (six studies) [85–90], Uganda (six studies) [22,91–95]
and Malawi (four studies) [7,22,96,97], with other countries
represented in two or fewer studies [98–100]. Ten of the
eighteen studies excluded patients on ART at the time of
enrolment. Two studies described fluconazole monotherapy as
the only regimen and a third RCT evaluated fluconazole as
one treatment arm [93,97,100], two RCTs evaluated combined
flucytosine and fluconazole therapy [7,97], and the rest
described use of amphotericin B with or without flucytosine
or fluconazole. Reasons for study exclusion are detailed in
Appendix S1: These included use of abnormal treatment regi-
mens [101–104], studies with non-representative sampling,
for example, delayed enrolment for one week after initiation
of antifungal therapy [14], and a study that reported longer-
term outcomes from only a subset of patients from an
included study [105]. For RCTs that compared standard
Records identified through database searching
(n = 3661)
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noitacifitnedI
Additional records identified through other 
sources
(n = 2 included from reference search)
Records after duplicates removed
(n = 2593)
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(n = 2593)
Records excluded
(n = 2321)
Full-text articles assessed for 
eligibility
(n = 272)
Full-text articles excluded, with 
reasons
(n = 193)
- 43 repeat from included study
- 37 with <15 eligible cases
- 22 no mortality outcomes
- 14 abstract only (e.g. conference)
- 13 non-representative sampling
- 11 inadequate diagnosis / non-
disaggregated outcomes
- 11 no treatment provided / non-
conventional treatment
- 11 large proportion outcomes 
missing
- 10 pediatric study
- 7 observational period <1990
- 7 review article
- 5 case series / research letters
- 2 not in sub-Saharan Africa
Studies included in qualitative 
synthesis
(n = 79)
Studies included in quantitative 
synthesis (meta-analysis)
(n = 79)
4 studies with 2 pathogens
Figure 2. PRISMA diagram.
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regimens to experimental regimens not part of clinical prac-
tice, for example, adjunctive interferon-gamma or sertraline
[87,106], or therapies demonstrated to be harmful, for exam-
ple, adjunctive dexamethasone [22], we restricted our analysis
to patients who received standard antifungal regimens. For
one RCT that recruited patients both in African and Asian
health centres, we restricted our analysis to patients from
Africa [22].
Short-term mortality was reported in 17 studies (all report-
ing two-week outcome) with 1991 cases. Pooled two-week
mortality was 21% (95% CI: 17% to 25%, I2 = 75%, 17 stud-
ies) (Figure 4). Stratified by treatment regimen, mortality was
12% (95% CI: 7% to 18%, I2 = 40%, 5 studies) for ampho-
tericin and flucytosine induction therapy, 17% (95% CI: 12%
to 22%, I2 = 0%, two studies) for flucytosine with fluconazole,
23% (95% CI: 19% to 28%, I2 = 72%, 12 studies) for ampho-
tericin with or without fluconazole and 30% (95% CI: 21% to
40%, I2 = 0%, three studies) for fluconazole alone. Little mor-
tality difference was observed for shorter (<2 weeks) and
longer (two-week) amphotericin-based induction regimens.
Medium-term mortality (at 10 weeks except four months in
one study [92]) was reported in 13 studies with 1487 cases,
with a pooled mortality of 37% (95% CI: 33% to 41%,
I2 = 42%) (Figure S4). Stratified by induction regimen, mortal-
ity was 30% (95% CI: 25% to 34%, I2 = 0%, five studies) for
amphotericin with flucytosine, 35% (95% CI: 29% to 42%,
I2 = 0%, two studies) for flucytosine with fluconazole, 39%
(95% CI: 35% to 43%, I2 = 14%, eight studies) for ampho-
tericin with or without fluconazole and 49% (95% CI: 39% to
60%, I2 = 29%, three studies) for fluconazole. Long-term mor-
tality (within six months except 18 weeks in one) was
described in six studies with 614 cases, with a pooled mortal-
ity of 44% (95% CI: 36% to 52%, I2 = 71%) (Figure S5).
Stratified by regimen, mortality was 33% (95% CI: 21% to
45%, one study) for amphotericin with flucytosine, 46% (95%
CI: 36% to 55%, I2 = 78%, four studies) for amphotericin with
or without fluconazole and 50% (95% CI: 30% to 70%, one
study) in a small study from Zimbabwe of fluconazole
monotherapy.
3.4 | TB meningitis outcomes
Twelve studies with 1008 TB meningitis cases were
included, all routine care studies and all but one with a
majority or all HIV positive (median 84%) [107]. One recent
study in Zambia, with 19% culture-confirmed adults TB
meningitis cases and a 86% HIV prevalence, contributed to
over half of these cases [108]. Study quality was relatively
low, with most studies not including details of ART or anti-
tuberculous treatment or average duration of hospitalization.
Five included cases before 2000 [34,109–112], whereas
seven had a full period of observation after 2000
[53,60,67,107,108,113,114]. Eight countries were repre-
sented, with greatest representation from South Africa
(three studies), Uganda (two studies) and Zambia (two stud-
ies). Six studies included exclusively definite cases (with pos-
itive CSF AFB smear, culture or PCR) and six included
mostly probable/possible cases (range 0% to 21% microbio-
logically confirmed, with two studies using Marais criteria
[25,108]). One study specified use of adjunctive dexametha-
sone [111]. Several potential studies were excluded on full-
text review (Appendix S1): Reasons included TB case series,
for example, exclusively multi-drug resistant cases [115–
117], high risk of selection bias [42,118–120], significant
missingness of outcomes [121–123] and unknown or inade-
quate description of diagnostic criteria [50,74,124–126].
Figure 3. Overall pooled short-term mortality of cryptococcal meningitis in routine care settings.
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Short-term mortality for 1008 cases was reported in 11
studies (two from a single hospital with combined patient out-
comes in Uganda [53,113] and two from a single hospital with
combined outcomes in Zambia [67,108]; two-week mortality
specified in one study [114], in-hospital mortality in ten stud-
ies with length of hospitalization not specified). Pooled mortal-
ity was 46% (95% CI: 33% to 59%, I2 = 92%, 11 studies)
(Figure 5), and was higher in studies with only definite cases
(51% (95% CI: 37% to 65%), I2 = 78%, six studies) and mostly
possible/probable cases (40% (95% CI: 23% to 59%), five
studies). Restricting to studies after 2000, pooled short-term
mortality was 42% (95% CI: 25% to 59%, I2 = 93%, seven
studies). Ten-week mortality from a national meningitis audit
in Botswana of microbiologically confirmed cases was 46%
(95% CI: 31% to 61%) [114]. Long-term mortality was
reported in two studies, within one year in the study from
Botswana and after completion of six months of antitubercu-
lous therapy in a Nigerian study [111], both studies with
exclusively definite cases. Reported mortality for these studies
was 56% (27/48) in Botswana and 78% (31/40) in Nigeria. Of
note, the Botswana study relied on national electronic death
registry data, which has been previously shown to accurately
capture deaths but might slightly under-estimate mortality
[56]. Long-term outcomes in the large study were excluded
because of high degree of data missingness (>20% at one
year) [108]. These investigators reported a one-year mortality
of 59% among patients who could be tracked, or 67% assum-
ing those lost to follow-up had died.
3.5 | Pneumococcal meningitis outcomes
Twelve studies with 3935 cases of pneumococcal meningitis
were included, a majority HIV-positive in nine studies, <50%
HIV positive in one, and with HIV prevalence not specified in
two studies. Nine were classified as routine care studies
[114,127–134] and two were RCTs [135,136]. One study con-
sisted of two sequential cohorts, a lead-in observational rou-
tine care cohort followed by a prospective cohort receiving a
bundled Goal Directed Therapy (GDT) intervention that
included parenteral ceftriaxone therapy within one hours of
registration, airway support, and fluid resuscitation according
to sepsis guidelines, among other supportive measures [137].
The clinical trial studies were judged to be of high quality, but
routine care studies of relatively low quality (including lack of
Figure 4. Pooled short-term mortality of cryptococcal meningitis in clinical trial settings.
Figure 5. Pooled short-term mortality of TB meningitis in routine care settings.
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description of ART status and dose and duration of antibiotic
therapy). Eight countries were represented, with four studies
(two RCTs, one observational cohort and the combined
sequential cohort study) from a single referral hospital in
Malawi. Nine studies included a full period of observation
after 2000. Ten provided outcomes for microbiologically con-
firmed cases (CSF culture, PCR, and/or antigen testing) and
two studies with Streptococcus pneumoniae microbiologically
confirmed for a majority of cases (64% to 69%). Treatment
varied significantly between studies; four described ceftriax-
one as standard antibiotic therapy (one RCT with adjunctive
dexamethasone used in a single treatment arm) [114,135],
two included chloramphenicol-based treatment as the predom-
inant treatment (one combined with intravenous penicillin G)
[127,129], two included aminopenicillins (amoxicillin or ampi-
cillin) with or without gentamycin as the predominant therapy
given [130,132], three studies did not specify therapy
[128,131,134], and one study included a similar mix of treat-
ment with ceftriaxone and chloramphenicol [133]. Several
potential studies were excluded on full text review
(Appendix S1): Reasons included a minority of cases with
Streptococcus pneumoniae isolation [34,138–140] and high loss
to follow-up / missing outcomes data [141–145].
Short-term mortality was reported in all nine routine care
studies with 3480 cases (including 14-day [114], 30-day [128],
in-hospital [129–132,134] and with length of follow-up not
specified in two surveillance studies but assumed short-term
[127,133]). Over half of these cases (64%, 2210/3480) were
from two surveillance studies in Gauteng Province, South
Africa [128,134]; the first from 2003 to 2008 reporting mor-
tality up to 30 days and the second with data from 2013 to
2016 with in-hospital mortality reported, with results pooled
together for the meta-analysis. Pooled mortality was 54%
(95% CI: 44% to 64%, I2 = 96%, nine studies) (Figure 6).
Medium- and long-term mortality was described in two rou-
tine care studies, one from Botswana and the other from
Malawi [114,129]. Both found generally favourable long-term
survival in those with short-term survival. The study from
Malawi showed a short-term (in-hospital up to nine days),
medium-term (10-week) and long-term (six-month) mortality
of 65% (42/65), 69% (45/65) and 69% (45/65) respectively,
with one-year mortality of 75% (49/65). The study from Bots-
wana found short-term (two-week), medium-term (10-weeks),
long-term (six-month) and one-year mortality of 44% (105/
238), 47% (112/238), 47% (113/238) and 49% (117/238)
respectively.
The two RCTs were both conducted at the same referral
hospital in Malawi, provided 40-day outcomes, and reported
treatment with ceftriaxone (with or without dexamethasone)
[135,136]. We combined data for patients treated with or
without adjunctive dexamethasone in one RCT as no differ-
ence in mortality was found between arms [136], and patients
receiving adjunctive glycerol in one RCT were excluded as
glycerol did not improve outcomes and may have been associ-
ated with severe adverse events [135]. Short-term (here
defined as 40-day) mortality ranged from 39% (20/51) to 51%
(140/272); however, mortality from pneumococcal meningitis
was certainly under-estimated in the smaller trial as 17% of
patients with suspected acute bacterial meningitis died before
they could be recruited. In the RCT with a 51% (140/272)
40-day mortality, long-term mortality was reported at 61%
(150/245) in patients not lost to follow-up.
The study with the combined sequential observational rou-
tine care cohort and interventional Goal Directed Therapy
cohort was conducted at the same centre as the two RCTs,
with ceftriaxone treatment provided as standard treatment
[137]. At the primary endpoint of 40 days, among patients
with known outcomes 49% (28/57) had died in the lead-in
observational cohort and 63% (38/60) in the subsequent clini-
cal trial cohort.
4 | DISCUSSION
This systematic review and meta-analysis provides compre-
hensive estimates of outcomes from common HIV-associated
meningitides in sub-Saharan Africa and addresses important
limitations of previous systematic reviews, including disaggre-
gation of mortality from clinical trial (prone to selection of
non-representative patients as well as more intensive manage-
ment) and routine care settings, and evaluation of outcomes
at different timepoints. Pooled mortality in routine care set-
tings was high, with approximately half of patients diagnosed
with cryptococcal, TB and pneumococcal meningitis dying
within two weeks or during hospitalization. Our results high-
light an overall poor understanding of long-term outcomes in
routine care settings given the lack of published outcomes.
Furthermore, most studies reported outcomes for patients
treated at referral centres, where staffing, pharmaceutical and
laboratory resources are likely better than in lower-level
health facilities. Our findings also suggest significant hetero-
geneity in mortality overall and between regions: Pooled
Figure 6. Pooled short-term mortality of pneumococcal meningitis in routine care settings.
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short-term mortality for cryptococcal meningitis in routine
care settings within Central and West Africa exceeded 50%,
compared to 37% in Southern Africa. The large heterogeneity
in outcome could be attributable to differences in resources
between regions and individual hospital facilities, intensity of
care received and time from symptoms onset to presentation
to care for patients, among other factors.
Comparing mortality of patients treated under routine care
conditions to clinical trial settings, we observed significant dif-
ferences for cryptococcal meningitis but similar mortality for
pneumococcal meningitis. Short-term mortality for cryptococ-
cal meningitis managed under routine care conditions was
twofold higher compared to mortality in clinical trial settings
(44% vs. 21%); which remained similar when stratified by
treatment regimen (e.g. 41% vs. 23% for amphotericin B with-
out flucytosine). This difference reflects a degree of differ-
ences in patients enrolled in clinical trials compared to routine
care studies (e.g. exclusion of more severely ill patients, such
as those with severe metabolic abnormalities or unable to
provide consent, in randomized-controlled trials). However,
this likely also reflects benefits from therapeutic lumbar punc-
tures, standardized intravenous fluid and electrolyte supple-
mentation, and better management of intravenous catheters
to prevent thrombophlebitis and catheter-associated bacter-
aemia in clinical trials [146]. In contrast, short-term mortality
from pneumococcal meningitis differed little between RCTs
and routine care settings, perhaps reflecting less intensive
management currently recommended for pneumococcal dis-
ease and highlighting a need for better management strate-
gies. In routine care settings, more than two-thirds of patients
died during the course of treatment for TB meningitis from
two studies, although data were not available to compare
these findings with clinical trials. This contrasts with 39% (68/
174) nine-month mortality in HIV-infected patients with TB
meningitis receiving standard treatment in a recent RCT from
Vietnam [147]. One prospective cohort from South Africa with
investigator management reported a 12% (3/34) nine-month
mortality of patients treated for HIV-associated TB meningitis
[42]; but this study excluded patients with severe TB and
those who did not initiate ART or were judged to have poor
drug adherence.
Our findings suggest that the previously estimated 70%
one-year mortality for HIV-associated cryptococcal meningitis
in sub-Saharan Africa may be conservative in some regions
[6], particularly Central and West Africa where pooled short-
term mortality exceeded 50% and long-term outcomes were
not reported. Our findings also suggest that improved avail-
ability of more fungicidal – but more toxic – amphotericin B
therapy alone may not have a large impact in reducing mortal-
ity. Under routine care settings, short-term mortality for
amphotericin-based and fluconazole-based regimens was simi-
lar at around 40% and long-term mortality was reported at
65% even with amphotericin B and high-dose fluconazole in
Botswana [56]. Recent evidence from a large RCT suggests
that, combined with flucytosine (5FC), a shortened one-week
course of amphotericin B is the most effective antifungal regi-
men to reduce mortality from HIV-associated cryptococcal
meningitis [7], with similar rates of early fungal clearance com-
pared to longer two-week courses and less drug toxicity [30].
Of a subset of participants from Malawi in this trial [105],
mortality remained relatively low at 28% (11/40) at one year
in the group treated with a one-week course of amphotericin
B combined with flucytosine. Thus, alongside expanding access
to amphotericin B formulations, there is an urgent need for
flucytosine access in sub-Saharan Africa as well as future out-
comes data evaluating this regimen in usual care settings. Fur-
thermore, standardized intravenous fluid and electrolyte
supplementation and therapeutic lumbar puncture schedules
are associated with improved outcomes in HIV-associated
cryptococcal meningitis and care checklists and protocols
could be operationalized even in many resource-limited set-
tings to reduce mortality [11,13].
Our study has a number of important limitations. First, we
applied strict diagnostic criteria. This resulted in the exclusion
of a number of TB meningitis studies in setting where micro-
biological tests (e.g. culture or PCR) were not available or a
majority of cases were diagnosed based on clinical suspicion
without clear diagnostic standards. This may have over-sam-
pled cases from clinical settings with better diagnostic capabil-
ity (e.g. TB PCR) or cases of TB meningitis with a higher CSF
bacillary burden. We found higher mortality in studies with
only microbiologically confirmed cases than in studies with
most cases diagnosed using combined laboratory, clinical, and/
or imaging features. Second, in comparing outcomes for cryp-
tococcal meningitis between routine care and clinical trial set-
tings, we were unable to determine the proportion of excess
mortality in routine care settings attributable to different fac-
tors (e.g. lack of therapeutic lumbar punctures vs. poor labora-
tory monitoring vs. poor completion of therapy). In reality, the
high mortality in routine care settings is likely multi-factorial
and our findings highlight the need for better management
strategies such as protocolized care, less toxic short-course
therapy, and better preventive strategies including CrAg
screening for individuals with advanced HIV/AIDS [21]. Third,
the classification of some prospective cohort studies as clinical
trials vs. routine care studies required some judgment by the
author team. Furthermore, patient enrolment in prospective
cohorts considered “routine care” studies may have led to bet-
ter clinical management from local clinicians as well as some
selection bias. Finally, duration of follow-up varied between
studies evaluating short-term mortality, and observational
studies of cryptococcal meningitis typically reported in-hospi-
tal rather than two-week mortality. This may have biased
results slightly toward a higher acute mortality in routine care
settings if length of stay was longer on average than two
weeks; however, the average length of hospitalization reported
from most studies was about two weeks.
5 | CONCLUSIONS
In conclusion, we found very high mortality from common
HIV-associated meningitides in sub-Saharan Africa, with
pooled short-term mortality for pneumococcal meningitis
around 50% and long-term mortality for TB and cryptococcal
meningitis well in excess of 50% but with an overall lack of
long-term outcomes data. Importantly, we found a significant
degree of heterogeneity in outcomes between different
regions of SSA, likely reflecting both relative resource-avail-
ability and other differences in management. Improved man-
agement strategies are needed and prevention efforts should
be prioritized, including CrAg screening for prevention of
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cryptococcal meningitis and childhood pneumococcal vaccina-
tion to provide some population herd immunity against inva-
sive pneumococcal disease [148].
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